
Halitosis Treatment Market Trends
Halitosis Treatment Market Research Report Information By Indication (Respiratory, Liver, Kidney, Gastrointestinal, Systemic, and Others), By Diagnostic Tests (Halimeter, Gas Chromatography, BANA Test, Β-Galactosidase Activity Assay, and Others), By Drug Treatment (Antacids, Antiseptics, Ranitidine, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market ...

Market Summary
The Global Halitosis Treatment Market is projected to grow significantly from 4.89 USD Billion in 2024 to 14.70 USD Billion by 2035.
Key Market Trends & Highlights
Halitosis Treatment Key Trends and Highlights
- The market is expected to experience a compound annual growth rate (CAGR) of 10.54% from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 14.7 USD Billion, indicating robust growth potential.
- in 2024, the market is valued at 4.89 USD Billion, reflecting the current demand for halitosis treatments.
- Growing adoption of innovative oral hygiene products due to increasing awareness of oral health is a major market driver.
Market Size & Forecast
2024 Market Size | 4.89 (USD Billion) |
2035 Market Size | 14.70 (USD Billion) |
CAGR (2025-2035) | 10.52% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
Colgate-Palmolive Company, All USA Partners LLC, Dr. Harold Katz, LLC, Rowpar Pharmaceuticals, Inc., Abbott, Listerine, AstraZeneca
Market Trends
Market CAGR for halitosis treatment is being driven by the rising treatment. Further factors driving the market's expansion include the increased incidence of periodontal disorders, rising alcohol and tobacco usage, tonsillitis, and inflammation of the nose, throat, and sinuses. Halitosis is believed to be the third most prevalent cause for seeing a dentist, after periodontal disease and dental caries, according to a study titled "The Prevalence and Determinant Factors of Oral Halitosis in Northwest Ethiopia: A Cross-Sectional Study" released by Dovepress in 2021. Between 22% and 50% of individuals worldwide reported having halitosis.
As a result, a key element anticipated to influence halitosis diagnosis and therapy shortly is the rising incidence of the condition worldwide.
Additionally, gum (periodontal) disease, closely related to halitosis, may show warning signs such as chronic foul breath or an unpleasant taste in the mouth. The prevalence of total periodontitis and stage III/IV periodontitis was 85.4% and 48.5%, respectively, according to a study titled "Periodontal Disease Prevalence, Extent, and Risk Associations in Untreated Individuals" that was released in January 2022 by the AAP and the EFP. 78.4% and 31.1%, respectively, of people had moderate-to-severe periodontitis, according to the CDC/AAP. Therefore, it is anticipated that the rising frequency of periodontal disorders will propel market expansion during the study period.
Halitosis is a widespread problem worldwide where severe instances only affect 5% of the population, but intermediate cases are common. The market is growing as the number of persons with halitosis increases and public knowledge of the condition and its treatment increases. In the US, almost 80 million people spend more than USD 10.75 billion yearly on dental care items. Thus, driving the Halitosis Treatment market revenue.
The increasing awareness of oral hygiene and the rising prevalence of halitosis among the global population suggest a growing demand for effective treatment options in the halitosis treatment market.
Centers for Disease Control and Prevention (CDC)
Halitosis Treatment Market Market Drivers
Market Growth Projections
Growth of the Dental Care Sector
The expansion of the dental care sector is significantly influencing the Global Halitosis Treatment Market Industry. As more individuals prioritize regular dental check-ups and preventive care, the likelihood of halitosis being diagnosed and treated increases. Dental professionals are increasingly incorporating discussions about bad breath into routine consultations, thereby raising awareness among patients. This proactive approach not only aids in early detection but also encourages the use of specialized products designed to combat halitosis. The synergy between dental care and halitosis treatment is likely to foster market growth, as consumers become more engaged in their oral health management.
Innovations in Treatment Options
Innovative advancements in treatment options for halitosis are propelling the Global Halitosis Treatment Market Industry forward. The introduction of new formulations, such as mouthwashes, sprays, and lozenges specifically designed to combat bad breath, is attracting consumer interest. For instance, products containing active ingredients like zinc compounds and essential oils are gaining popularity due to their effectiveness in neutralizing odor-causing bacteria. Furthermore, the development of personalized oral care solutions, which cater to individual needs, is likely to enhance consumer satisfaction and loyalty. This trend suggests a robust growth trajectory for the market, with a projected CAGR of 10.54% from 2025 to 2035.
Rising Awareness of Oral Hygiene
The increasing awareness regarding oral hygiene and its direct correlation with halitosis is a significant driver for the Global Halitosis Treatment Market Industry. Educational campaigns by dental associations and health organizations emphasize the importance of maintaining oral health, thereby encouraging consumers to seek effective treatments for bad breath. As individuals become more informed about the causes of halitosis, including poor dental care and certain medical conditions, the demand for specialized products and treatments is likely to rise. This heightened awareness is expected to contribute to the market's growth, with projections indicating a market value of 4.89 USD Billion in 2024.
Consumer Demand for Natural Products
The growing consumer preference for natural and organic products is shaping the Global Halitosis Treatment Market Industry. Many individuals are becoming more health-conscious and are seeking treatments that align with their values regarding sustainability and natural ingredients. This trend is evident in the rising popularity of mouthwashes and sprays made from herbal extracts and essential oils, which are perceived as safer alternatives to synthetic products. As manufacturers respond to this demand by developing natural formulations, the market is likely to witness an increase in product offerings. This shift towards natural solutions may further enhance the overall growth of the halitosis treatment market.
Increasing Prevalence of Oral Diseases
The rising prevalence of oral diseases, such as periodontal disease and dry mouth, is a crucial factor driving the Global Halitosis Treatment Market Industry. These conditions often lead to halitosis, prompting individuals to seek effective treatments. According to health statistics, a significant portion of the global population experiences some form of oral disease, which can exacerbate bad breath. As healthcare providers focus on preventive care and treatment options, the demand for halitosis solutions is expected to surge. This trend is indicative of a broader public health concern, with the market anticipated to reach 14.7 USD Billion by 2035, reflecting the urgent need for effective interventions.
Market Segment Insights
Halitosis Treatment Indication Insights
Based on indication, the Halitosis Treatment market segmentation includes respiratory, liver, kidney,
gastrointestinal,
systemic, and others. The liver segment dominated the market, accounting for 35% of market revenue. Trimethylamine is more prevalent in cirrhotic patients, which leads to bad breath. One of the odd symptoms of fatty liver disease is "breath of the dead." The Fetor hepaticus, often known as the breath of the dead, is a lingering odor that differs from typical breath. Hepatitis and liver failure are intimately connected to fetor hepaticus.
Organ-related bad breath is typically caused by a sickness or food that interacts with blood levels and generates an odor. Since liver illnesses and bad breath are frequently linked, the rise in liver diseases is anticipated to accelerate the segment's growth throughout the projected period.
Halitosis Treatment Diagnostic Tests Insights
Based on diagnostic tests, the Halitosis Treatment market segmentation includes an altimeter, gas
chromatography
, BANA test, and Β-galactosidase activity assay. The BANA test segment dominated the market. The BANA test assesses the proteolytic activity of certain oral anaerobes that contribute to oral malodor. It refers to the enzymatic breakdown of [N-benzoyl-dL-arginine-2-napthylamide]. Treponema denticola, Prophyromona gingivitis, and Bacteroides forsythias (Red complex) are a few bacteria that create waste products that are highly odiferous and, as a result, contribute to foul breath. The N-benzoyl enzyme is destroyed when a patient's saliva sample containing these bacteria is added to the BANA testing chemical. The test substance changes color due to this biodegradation, indicating a successful response.
Halitosis Treatment Drug Treatment Insights
The Halitosis Treatment market segmentation, based on Drug Treatment, includes antacids, antiseptics, ranitidine, and others. The antacids generated the most income. Antacids are frequently used since they are affordable and help to reduce the discomfort, irritation, edema, and inflammation brought on by heartburn. Additionally, several product advancements, such as creating powerful and safe raft-forming antacids that offer improved efficacy and a longer duration of action, are boosting the market's expansion. The market is expected to develop due to the increasing use of chewable tablets in various flavors that are convenient to store, deliver the right dosage, and enhance patient adherence.
Figure 1: Halitosis Treatment Market, by Drug Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Get more detailed insights about Halitosis Treatment Market Research Report- Forecast till 2032
Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Halitosis Treatment market area will dominate this market due to an increase in periodontal disorders, a rise in halitosis prevalence, and increased general knowledge of the condition and its treatment options.
Further, the major countries studied in the market report are The US, Canada, the UK, Italy, Spain, China, Japan, India, German, France, Australia, South Korea, and Brazil.
Figure 2: HALITOSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Europe has the second-largest market share for Halitosis Treatment. Due to rising oral hygiene awareness among people and rising diagnostic and therapeutic options for treating foul breath in several regional nations, the increasing prevalence of chronic illnesses like diabetes, respiratory conditions, and renal or liver failure with the growing population. Growing older adults with various conditions also contribute to the market's expansion. Furthermore, the German Halitosis Treatment market dominated, while the UK Halitosis Treatment market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Halitosis Treatment Market will develop at the quickest CAGR. A rise in knowledge about halitosis and the treatments available to cure it. Additionally, rising consumer desire for novel dental care products impacts market expansion. The region's residents make significant financial investments in healthcare, particularly dental care. Future growth of the market is predicted. Furthermore, China's Halitosis Treatment market had the highest market share, whereas India's Halitosis Treatment market was the Asia-Pacific region's fastest growing.
Key Players and Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Halitosis Treatment market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Halitosis Treatment industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Halitosis Treatment industry to serve clients and expand the market sector. The Halitosis Treatment industry has provided some of the most important benefits recently. Church & Dwight., Colgate-Palmolive, and other major companies in the Halitosis Treatment market are aiming to enhance market demand by investing in research and development activities
American consumer goods corporation Colgate-Palmolive has its main office on Park Avenue in Midtown Manhattan, New York City. Production, distribution, and provision of domestic, health, personal care, and veterinary items are the company's areas of expertise. The biggest manufacturer of soap and detergent in the world, Procter & Gamble (P&G), has long been a rival of Colgate-Palmolive. Following World War II, P&G launched their Tide laundry detergent, which attracted thousands of customers away from Colgate's soaps. When P&G introduced fluoride to their toothpaste, Colgate lost its top spot in the market (Colgate has subsequently reclaimed the top sales spot).
In May 2021, In the United States, Colgate's Hello Products debuted fresh, natural, and eco-friendly oral care items like a reusable toothbrush, floss flavored with peppermint oil and coconut oil, tablets that freshen breath, and mouthwashes.
The market leader in home and personal care goods is Church & Dwight. ARM & HAMMER, Batiste, OxiClean, Trojan, XTRA, Nair, First Response, Spinbrush, Orajel, vita fusion, Li'l Critters, Water Pik, FLAWLESS, Zicam, and TheraBreath are just a few of our internationally recognized brands. They were established in 1846, operate internationally, and are included in the S&P 500. At Church & Dwight, they fuel people's daily lives by offering high-quality, cost-effective consumer goods. Where impact meets ambition is here. They are proud to be experts in our fields. Their team of highly skilled individuals innovates and concentrates on innovative methods.
In November 2021, Church & Dwight Co., Inc. signed a legally binding contract to buy the TheraBreath name. TheraBreath is the second most popular brand of alcohol-free mouthwash in the US. Therefore, these advancements will probably help the market in North America flourish.
Key Companies in the Halitosis Treatment Market market include

Industry Developments
- Q2 2024: TheraBreath Launches New Oral Rinse Targeting Halitosis TheraBreath announced the launch of a new oral rinse specifically formulated to target halitosis, expanding its product portfolio in the oral care market.
- Q2 2024: GSK Introduces Sensodyne Fresh Breath Toothpaste for Halitosis Relief GlaxoSmithKline launched Sensodyne Fresh Breath Toothpaste, designed to address halitosis while providing sensitivity relief, marking a new addition to its oral health product line.
- Q3 2024: Oral Science Announces Partnership with Dental Clinics for Halitosis Treatment Program Oral Science entered into a partnership with a network of dental clinics to implement a specialized halitosis treatment program using its proprietary products.
- Q3 2024: Colgate-Palmolive Expands Manufacturing Facility for Halitosis Treatment Products Colgate-Palmolive announced the expansion of its manufacturing facility in New Jersey to increase production capacity for its halitosis treatment product line.
- Q4 2024: FDA Approves New Prescription Mouthwash for Chronic Halitosis The U.S. FDA approved a new prescription mouthwash developed for chronic halitosis, marking a regulatory milestone for advanced oral care therapeutics.
- Q4 2024: Johnson & Johnson Acquires BreathRx Brand to Strengthen Halitosis Portfolio Johnson & Johnson completed the acquisition of the BreathRx brand, enhancing its portfolio of products targeting halitosis and oral malodor.
- Q1 2025: LISTERINE Launches Advanced Formula for Bad Breath in Asia-Pacific LISTERINE introduced an advanced mouthwash formula targeting bad breath in the Asia-Pacific region, aiming to capture growing demand for halitosis solutions.
- Q1 2025: Oral Care Startup BreathWell Raises $15M Series A to Develop Halitosis Diagnostic Device BreathWell, a health tech startup, secured $15 million in Series A funding to accelerate development of its non-invasive halitosis diagnostic device.
- Q2 2025: Procter & Gamble Announces Strategic Partnership with Dental Chain for Halitosis Education Procter & Gamble formed a strategic partnership with a major dental chain to launch a halitosis education and treatment initiative across multiple clinics.
- Q2 2025: FreshBreath Technologies Files for IPO to Fund Halitosis Treatment Product Expansion FreshBreath Technologies filed for an initial public offering, aiming to raise capital for expanding its halitosis treatment product line and global distribution.
- Q3 2025: Dentek Unveils New Tongue Cleaner for Halitosis Prevention Dentek launched a new tongue cleaner designed to help prevent halitosis, broadening its oral hygiene product offerings.
- Q3 2025: Novartis Receives European Approval for Halitosis Treatment Tablet Novartis received regulatory approval in Europe for its new tablet indicated for the treatment of halitosis, expanding its presence in the oral care therapeutics market.
Future Outlook
Halitosis Treatment Market Future Outlook
The Halitosis Treatment Market is projected to grow at a 10.52% CAGR from 2025 to 2035, driven by increasing awareness of oral hygiene, technological advancements, and rising demand for effective treatments.
New opportunities lie in:
- Develop innovative, natural-based halitosis treatments targeting health-conscious consumers.
- Leverage telehealth platforms for remote consultations and personalized treatment plans.
- Expand distribution channels through e-commerce to reach a broader audience globally.
By 2035, the Halitosis Treatment Market is expected to be robust, reflecting significant advancements and consumer engagement.
Market Segmentation
Halitosis Treatment Regional Outlook
- US
- Canada
Halitosis Treatment Indication Outlook
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
Halitosis Treatment Diagnostic Tests Outlook
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
Halitosis Treatment Drug Treatment Outlook
- Antacids
- Antiseptics
- Ranitidine
- Others
Report Scope
Attribute/Metric | Details |
Market Size 2024 | USD 4.89 Billion |
Market Size 2035 | 14.70 (Value (USD Billion)) |
Compound Annual Growth Rate (CAGR) | 10.52% (2025 - 2035) |
Base Year | 2024 |
Market Forecast Period | 2025 - 2035 |
Historical Data | 2019- 2022 |
Market Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Drug Treatment, and Region |
Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled | Colgate-Palmolive Company (U.S), All USA Partners LLC (U.S), Dr. Harold Katz, LLC (U.S), Rowpar Pharmaceuticals, Inc. (U.S), Abbott (U.S), Listerine (U.S), AstraZeneca (U.S) |
Key Market Opportunities | Dental Health Care Products |
Key Market Dynamics | Rising incidence of periodontal disease |
Market Size 2025 | 5.40 (Value (USD Billion)) |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
How much is the Halitosis Treatment market?
The Halitosis Treatment market size was valued at USD 4.37 Billion in 2023.
What is the growth rate of the Halitosis Treatment market?
The market is projected to grow at a CAGR of 10.52% during the forecast period, 2024-2032.
Which region held the largest market share in the Halitosis Treatment market?
North America had the largest share in the market
Who are the key players in the Halitosis Treatment market?
The key players in the market are Colgate-Palmolive Company (U.S), All USA Partners LLC (U.S), Dr. Harold Katz, LLC (U.S), Rowpar Pharmaceuticals, Inc. (U.S),
Which type led the Halitosis Treatment market?
The Liver dominated the market in 2023.
Which Drug Treatment had the largest market share in the Halitosis Treatment market?
The antacids had the largest share in the market.
-
REPORT PROLOGUE
-
Market Introduction
- INTRODUCTION 17
- SCOPE OF STUDY 17
- RESEARCH OBJECTIVE 17
-
ASSUMPTIONS & LIMITATIONS 18
- ASSUMPTIONS 18
- LIMITATIONS 18
- MARKET STRUCTURE 19
-
Research Methodology: HALITOSIS MARKET
- RESEARCH PROCESS 20
-
MARKET SIZE ESTIMATION 22
- MARKET SHARE ANALYSIS 23
- FORECAST MODEL 24
-
MARKER DYNAMICS
-
DRIVERS 25
- RISING PREVALENCE OF PERIODONTAL DISEASES 25
- GERIATRIC POPULATION 25
- AVAILABILITY OF WIDE RANGE OF PRODUCTS 25
- INCREASING PREVALENCE OF CHRONIC DISEASES 25
-
RESTRAINTS 26
- LACK OF AWARENESS ABOUT HALITOSIS AND ITS TREATMENT 26
- ALTERNATIVE TREATMENT 26
-
OPPORTUNITIES 26
- TECHNOLOGICAL ADVANCEMENT 26
-
MEGA TRENDS 26
- SHIFT FROM DIAGNOSIS TO MANAGEMENT 26
- NANO SENSOR FOR DISEASE DIAGNOSIS 27
- MACROECONOMIC INDICATORS 27
-
DRIVERS 25
-
MARKET FACTOR ANALYSIS
-
PORTER’S FIVE FORCES MODEL 28
- BARGAINING POWER OF SUPPLIERS 29
- BARGAINING POWER OF BUYERS 29
- THREAT OF NEW ENTRANTS 29
- THREAT OF SUBSTITUTES 29
- INTENSITY OF RIVALRY 29
-
VALUE CHAIN ANALYSIS 30
- R&D 30
- MANUFACTURING 30
- DISTRIBUTION & SALES 31
- POST-SALES SERVICES 31
- PRICING ANALYSIS 32
- INVESTMENT OPPORTUNITY ANALYSIS 33
-
PORTER’S FIVE FORCES MODEL 28
-
HALITOSIS TREATMENT MARKET, BY TYPE
- INTRODUCTION 34
- PATHOLOGIC HALITOSIS 36
- OTHER HALITOSIS 37
-
HALITOSIS TREATMENT MARKET, BY INDICATION
- INTRODUCTION 38
- RESPIRATORY DISORDERS 39
- LIVER DISORDERS 41
- KIDNEY DISORDER 42
- GASTROINTESTINAL DISORDERS 43
- SYSTEMIC DISORDERS 44
-
HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
- INTRODUCTION 45
- HALIMETER 46
- GAS CHROMATOGRAPHY 47
- BANA TEST 48
- B- GALACTOSIDASE ACTIVITY ASSAY 49
- OTHER TESTS 50
-
HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
- INTRODUCTION 51
- ANTACIDS 53
- ANTISEPTICS 54
- RANITIDINE 55
- OTHER TREATMENTS 56
-
GLOBAL HALITOSIS TREATMENT MARKET, BY REGION
- INTRODUCTION 57
- AMERICAS 58
-
HALITOSIS TREATMENT MARKET, BY TYPE
-
HALITOSIS TREATMENT MARKET, BY INDICATION
-
HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
-
HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
- U.S. 63
-
HALITOSIS TREATMENT MARKET, BY TYPE
-
HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
-
HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
- CANADA 66
-
HALITOSIS TREATMENT MARKET, BY INDICATION
-
HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
- SOUTH AMERICA 69
-
HALITOSIS TREATMENT MARKET, BY TYPE
-
HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
- EUROPE 73
-
HALITOSIS TREATMENT MARKET, BY INDICATION
-
GERMANY 77
- FRANCE 80
-
GERMANY 77
-
HALITOSIS TREATMENT MARKET, BY INDICATION
-
UK 83
- ITALY 86
- SPAIN 89
- EASTERN EUROPE 92
-
ASIA PACIFIC 96
- JAPAN 100
- CHINA 103
- INDIA 106
-
UK 83
-
HALITOSIS TREATMENT MARKET, BY TYPE
-
HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
-
AUSTRALIA 109
- REPUBLIC OF KOREA 112
-
AUSTRALIA 109
-
HALITOSIS TREATMENT MARKET, BY INDICATION
-
HALITOSIS TREATMENT MARKET, BY DRUG TREATMENT
- REST OF ASIA PACIFIC 115
- MIDDLE EAST & AFRICA 118
-
HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST
-
MIDDLE EAST 122
- AFRICA 125
-
MIDDLE EAST 122
-
Competitive Landscape
- INTRODUCTION 129
- COMPANY SHARE ANALYSIS 130
-
ABBOTT 131
- COMPANY OVERVIEW 131
- PRODUCT/BUSINESS SEGMENT OVERVIEW 131
- FINANCIAL UPDATES 131
- KEY DEVELOPMENTS 133
- SWOT ANALYSIS 133
-
ALL USA PARTNERS LLC 134
- COMPANY OVERVIEW 134
- PRODUCT/BUSINESS SEGMENT OVERVIEW 134
- FINANCIAL UPDATES 134
- KEY DEVELOPMENTS 134
- SWOT ANALYSIS 135
-
ASTRAZENECA 136
- COMPANY OVERVIEW 136
- PRODUCT/BUSINESS SEGMENT OVERVIEW 136
- FINANCIAL OVERVIEW 136
- KEY DEVELOPMENT 137
- SWOT ANALYSIS 138
-
COLGATE-PALMOLIVE COMPANY 139
- COMPANY OVERVIEW 139
- PRODUCT/BUSINESS SEGMENT OVERVIEW 139
- FINANCIAL UPDATES 139
- KEY DEVELOPMENTS 140
- SWOT ANALYSIS 141
-
DR. HAROLD KATZ, LLC 142
- COMPANY OVERVIEW 142
- PRODUCT/BUSINESS SEGMENT OVERVIEW 142
- FINANCIAL UPDATES 142
- KEY DEVELOPMENTS 142
- SWOT ANALYSIS 143
-
LISTERINE (PART OF JOHNSON & JOHNSON) 144
- COMPANY OVERVIEW 144
- PRODUCT/BUSINESS SEGMENT OVERVIEW 144
- FINANCIAL UPDATES 144
- KEY DEVELOPMENTS 145
- SWOT ANALYSIS 146
-
ROWPAR PHARMACEUTICALS, INC. 147
- COMPANY OVERVIEW 147
- PRODUCT/BUSINESS SEGMENT OVERVIEW 147
- FINANCIAL UPDATES 147
- KEY DEVELOPMENTS 147
- SWOT ANALYSIS 148
-
MRFR CONCLUSION
-
Key Findings 149
- FROM CEO’S VIEW POINT 149
- UNMET NEEDS 149
- KEY COMPANIES TO WATCH 149
-
Key Findings 149
-
APPENDIX
- DISCUSSION BLUE PRINT 150
- REFERENCES 152
-
List of Tables and Figures
- 14 List of Tables
- TABLE 1 GLOBAL HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 34
- TABLE 2 GLOBAL HALITOSIS TREATMENT MARKET FOR PATHOLOGIC HALITOSIS, BY REGION, 2023-2030 (USD MILLION) 36
- TABLE 3 GLOBAL HALITOSIS TREATMENT MARKET FOR OTHER HALITOSIS, BY REGION, 2023-2030 (USD MILLION) 37
- TABLE 4 GLOBAL HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 38
- TABLE 5 GLOBAL HALITOSIS TREATMENT MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023-2030 (USD MILLION) 40
- TABLE 6 GLOBAL HALITOSIS TREATMENT MARKET FOR LIVER DISORDERS, BY REGION, 2023-2030 (USD MILLION) 41
- TABLE 7 GLOBAL HALITOSIS TREATMENT MARKET FOR KIDNEY DISORDER, BY REGION, 2023-2030 (USD MILLION) 42
- TABLE 8 GLOBAL HALITOSIS TREATMENT MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2023-2030 (USD MILLION) 43
- TABLE 9 GLOBAL HALITOSIS TREATMENT MARKET FOR SYSTEMIC DISORDERS, BY REGION, 2023-2030 (USD MILLION) 44
- TABLE 10 GLOBAL HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 45
- TABLE 11 GLOBAL HALITOSIS TREATMENT MARKET FOR HALIMETER, BY REGION, 2023-2030 (USD MILLION) 47
- TABLE 12 GLOBAL HALITOSIS TREATMENT MARKET FOR GAS CHROMATOGRAPHY, BY REGION, 2023-2030 (USD MILLION) 48
- TABLE 13 GLOBAL HALITOSIS TREATMENT MARKET FOR BANA TEST, BY REGION, 2023-2030 (USD MILLION) 48
- TABLE 14 GLOBAL HALITOSIS TREATMENT MARKET FOR B- GALACTOSIDASE ACTIVITY ASSAY, BY REGION, 2023-2030 (USD MILLION) 49
- TABLE 15 GLOBAL HALITOSIS TREATMENT MARKET FOR OTHER TESTS, BY REGION, 2023-2030 (USD MILLION) 50
- TABLE 16 GLOBAL HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 51
- TABLE 17 GLOBAL HALITOSIS TREATMENT MARKET FOR ANTACIDS, BY REGION, 2023-2030 (USD MILLION) 53
- TABLE 18 GLOBAL HALITOSIS TREATMENT MARKET FOR ANTISEPTICS, BY REGION, 2023-2030 (USD MILLION) 54
- TABLE 19 GLOBAL HALITOSIS TREATMENT MARKET FOR RANITIDINE, BY REGION, 2023-2030 (USD MILLION) 55
- TABLE 20 GLOBAL HALITOSIS TREATMENT MARKET FOR OTHER TREATMENT, BY REGION, 2023-2030 (USD MILLION) 56
- TABLE 21 GLOBAL HALITOSIS TREATMENT MARKET, BY REGION, 2023-2030 (USD MILLION) 57
- TABLE 22 AMERICAS HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 59
- TABLE 23 AMERICAS HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 60
- TABLE 24 AMERICAS HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 60
- TABLE 25 AMERICAS HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 61
- TABLE 26 AMERICAS HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 62
- TABLE 27 U.S. HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 63
- TABLE 28 U.S. HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 64
- TABLE 29 U.S. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 65
- TABLE 30 U.S. HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 65
- TABLE 31 CANADA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 66
- TABLE 32 CANADA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 67
- TABLE 33 CANADA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 68
- TABLE 34 CANADA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 68
- TABLE 35 SOUTH AMERICA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 69
- TABLE 36 SOUTH AMERICA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 70
- TABLE 37 SOUTH AMERICA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 71
- TABLE 38 SOUTH AMERICA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 71
- TABLE 39 EUROPE HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 73
- TABLE 40 EUROPE HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 74
- TABLE 41 EUROPE HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 75
- TABLE 42 EUROPE HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 76
- TABLE 43 EUROPE HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 76
- TABLE 44 GERMANY HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 77
- TABLE 45 GERMANY HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 78
- TABLE 46 GERMANY HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 79
- TABLE 47 GERMANY HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 79
- TABLE 48 FRANCE HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 80
- TABLE 49 FRANCE HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 81
- TABLE 50 FRANCE HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 82
- TABLE 51 FRANCE HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 82
- TABLE 52 UK HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 83
- TABLE 53 UK HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 84
- TABLE 54 U.K. HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 85
- TABLE 55 UK HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 85
- TABLE 56 ITALY HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 86
- TABLE 57 ITALY HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 87
- TABLE 58 ITALY HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 88
- TABLE 59 ITALY HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 88
- TABLE 60 SPAIN HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 89
- TABLE 61 SPAIN HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 90
- TABLE 62 SPAIN HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 91
- TABLE 63 SPAIN HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 91
- TABLE 64 EASTERN EUROPE HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 92
- TABLE 65 EASTERN EUROPE HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 93
- TABLE 66 EASTERN EUROPE HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 94
- TABLE 67 EASTERN EUROPE HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 94
- TABLE 68 ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 96
- TABLE 69 ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 97
- TABLE 70 ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 98
- TABLE 71 ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 99
- TABLE 72 ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 99
- TABLE 73 JAPAN HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 100
- TABLE 74 JAPAN HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 101
- TABLE 75 JAPAN HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 102
- TABLE 76 JAPAN HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 102
- TABLE 77 CHINA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 103
- TABLE 78 CHINA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 104
- TABLE 79 CHINA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 105
- TABLE 80 CHINA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 105
- TABLE 81 INDIA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 106
- TABLE 82 INDIA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 107
- TABLE 83 INDIA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 108
- TABLE 84 INDIA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 108
- TABLE 85 AUSTRALIA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 109
- TABLE 86 AUSTRALIA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 110
- TABLE 87 AUSTRALIA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 111
- TABLE 88 AUSTRALIA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 111
- TABLE 89 REPUBLIC OF KOREA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 112
- TABLE 90 REPUBLIC OF KOREA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 113
- TABLE 91 REPUBLIC OF KOREA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 114
- TABLE 92 REPUBLIC OF KOREA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 114
- TABLE 93 REST OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 115
- TABLE 94 REST OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 116
- TABLE 95 REST OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 117
- TABLE 96 REST OF ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 117
- TABLE 97 MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 118
- TABLE 98 MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 119
- TABLE 99 MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 120
- TABLE 100 MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 121
- TABLE 101 MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 121
- TABLE 102 MIDDLE EAST HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 122
- TABLE 103 MIDDLE EAST HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 123
- TABLE 104 MIDDLE EAST HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 124
- TABLE 105 MIDDLE EAST HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 124
- TABLE 106 AFRICA HALITOSIS TREATMENT MARKET, BY TYPE, 2023-2030 (USD MILLION) 125
- TABLE 107 AFRICA HALITOSIS TREATMENT MARKET, BY INDICATION, 2023-2030 (USD MILLION) 126
- TABLE 108 AFRICA HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023-2030 (USD MILLION) 127
- TABLE 109 AFRICA HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023-2030 (USD MILLION) 127
- TABLE 110 ABBOTT: KEY DEVELOPMENTS 133
- TABLE 111 ROWPAR PHARMACEUTICALS, INC.: KEY DEVELOPMENTS 147 15 List of Figures
- FIGURE 1 GLOBAL HALITOSIS MARKET, BY TYPE, 2023 (%) 13
- FIGURE 2 GLOBAL HALITOSIS MARKET, BY INDICATION, 2023 (%) 13
- FIGURE 3 GLOBAL HALITOSIS MARKET, BY DIAGNOSTIC TEST, 2023 (%) 14
- FIGURE 4 GLOBAL HALITOSIS MARKET, BY TREATMENT, 2023 (%) 15
- FIGURE 5 GLOBAL HALITOSIS MARKET, BY REGION, 2023 (%) 16
- FIGURE 6 GLOBAL HALITOSIS MARKET: MARKET STRUCTURE 19
- FIGURE 7 RESEARCH PROCESS 20
- FIGURE 8 MARKET ASSESMENT: TRAIGULATION APPROACH 21
- FIGURE 9 GLOBAL HALITOSIS MARKET: FORECAST MODEL 24
- FIGURE 10 PORTERS FIVE FORCES MODEL 28
- FIGURE 11 VALUE CHAIN: HALITOSIS 30
- FIGURE 12 GLOBAL HALITOSIS TREATMENT MARKET, BY TYPE, 2023 & 2030 (USD MILLION) 35
- FIGURE 13 GLOBAL HALITOSIS TREATMENT MARKET, BY INDICATION, 2023 & 2030 (USD MILLION) 39
- FIGURE 14 GLOBAL HALITOSIS TREATMENT MARKET, BY DIAGNOSTIC TEST, 2023 & 2030 (USD MILLION) 46
- FIGURE 15 GLOBAL HALITOSIS TREATMENT MARKET, BY TREATMENT, 2023 & 2030 (USD MILLION) 52
- FIGURE 16 GLOBAL HALITOSIS TREATMENT MARKET, BY REGION, 2023 & 2030 (USD MILLION) 58
- FIGURE 17 AMERICAS HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 59
- FIGURE 18 EUROPE HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 74
- FIGURE 19 ASIA PACIFIC HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 97
- FIGURE 20 MIDDLE EAST & AFRICA HALITOSIS TREATMENT MARKET, BY COUNTRY, 2023 (%) 118
- FIGURE 21 GLOBAL HALITOSIS MARKET: Competitive Landscape 129
- FIGURE 22 GLOBAL HALITOSIS MARKET: COMPANY SHARE ANALYSIS 130
- FIGURE 23 ABBOTT: RECENT FINANCIALS (USD MILLION) 131
- FIGURE 24 ABBOTT: GEOGRAPHICAL REVENUE, 2023 (%) 132
- FIGURE 25 ABBOTT: SEGMENTAL REVENUE, 2023 (%) 132
- FIGURE 26 ABBOTT: SWOT ANALYSIS 133
- FIGURE 27 ALL USA PARTNERS LLC: SWOT ANALYSIS 135
- FIGURE 28 ASTRAZENECA: RECENT FINANCIAL 136
- FIGURE 29 ASTRAZENECA: OPERATING SEGMENTS 137
- FIGURE 30 ASTRAZENECA: GEOGRAPHICAL MIX 137
- FIGURE 31 ASTRAZENECA: SWOT ANALYSIS 138
- FIGURE 32 COLGATE-PALMOLIVE COMPANY: RECENT FINANCIALS (USD MILLION) 139
- FIGURE 33 COLGATE-PALMOLIVE COMPANY: GEOGRAPHICAL REVENUE, 2023 (%) 140
- FIGURE 34 COLGATE-PALMOLIVE COMPANY: SEGMENTAL REVENUE, 2023 (%) 140
- FIGURE 35 COLGATE-PALMOLIVE COMPANY: SWOT ANALYSIS 141
- FIGURE 36 DR. HAROLD KATZ, LLC: SWOT ANALYSIS 143
- FIGURE 37 LISTERINE: RECENT FINANCIALS (USD MILLION) 144
- FIGURE 38 LISTERINE: GEOGRAPHICAL REVENUE, 2023 (%) 145
- FIGURE 39 LISTERINE: SEGMENTAL REVENUE, 2023 (%) 145
- FIGURE 40 LISTERINE: SWOT ANALYSIS 146
- FIGURE 41 ROWPAR PHARMACEUTICALS, INC.: SWOT ANALYSIS 148
Market Segmentation
Halitosis Treatment Indication Outlook (USD Billion, 2018-2032)
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
Halitosis Treatment Diagnostic Tests Outlook (USD Billion, 2018-2032)
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
Halitosis Treatment Drug Treatment Outlook (USD Billion, 2018-2032)
- Antacids
- Antiseptics
- Ranitidine
- Others
Halitosis Treatment Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
- North America Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- North America Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- North America Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
US Outlook (USD Billion, 2018-2032)
- US Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- US Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- US Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
CANADA Outlook (USD Billion, 2018-2032)
- CANADA Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- CANADA Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- CANADA Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
- North America Halitosis Treatment by Indication
Europe Outlook (USD Billion, 2018-2032)
- Europe Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Europe Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Europe Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Germany Outlook (USD Billion, 2018-2032)
- Germany Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Germany Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Germany Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
France Outlook (USD Billion, 2018-2032)
- France Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- France Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- France Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
UK Outlook (USD Billion, 2018-2032)
- UK Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- UK Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- UK Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
ITALY Outlook (USD Billion, 2018-2032)
- ITALY Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- ITALY Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- ITALY Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
SPAIN Outlook (USD Billion, 2018-2032)
- Spain Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Spain Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Spain Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Rest Of Europe Outlook (USD Billion, 2018-2032)
- Rest Of Europe Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Rest Of Europe Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Rest Of Europe Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
- Europe Halitosis Treatment by Indication
Asia-Pacific Outlook (USD Billion, 2018-2032)
- Asia-Pacific Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Asia-Pacific Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Asia-Pacific Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
China Outlook (USD Billion, 2018-2032)
- China Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- China Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- China Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Japan Outlook (USD Billion, 2018-2032)
- Japan Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Japan Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Japan Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
India Outlook (USD Billion, 2018-2032)
- India Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- India Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- India Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Australia Outlook (USD Billion, 2018-2032)
- Australia Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Australia Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Australia Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
- Rest of Asia-Pacific Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Rest of Asia-Pacific Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Rest of Asia-Pacific Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
- Asia-Pacific Halitosis Treatment by Indication
Rest of the World Outlook (USD Billion, 2018-2032)
- Rest of the World Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Rest of the World Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Rest of the World Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Middle East Outlook (USD Billion, 2018-2032)
- Middle East Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Middle East Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Middle East Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Africa Outlook (USD Billion, 2018-2032)
- Africa Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Africa Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Africa Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
Latin America Outlook (USD Billion, 2018-2032)
- Latin America Halitosis Treatment by Indication
- Respiratory
- Liver
- Kidney
- Gastrointestinal
- Systemic
- Others
- Latin America Halitosis Treatment by Diagnostic Tests
- Halimeter
- Gas Chromatography
- BANA Test
- Β-Galactosidase Activity Assay
- Others
- Latin America Halitosis Treatment by Drug Treatment
- Antacids
- Antiseptics
- Ranitidine
- Others
- Rest of the World Halitosis Treatment by Indication

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment